Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Subscribe To Our Newsletter & Stay Updated
